Fabian Model
14Patents
3h-index
37Co-inventors
56Inventor score
Filing activity: Jun 13, 2002 → Jun 26, 2019
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US7749702B2 | Methods and nucleic acids for the analyses of cellular proliferative disorders | Chemistry; Metallurgy | 24 | Active |
| US8900829B2 | Methods and nucleic acids for analyses of cellular proliferative disorders | Chemistry; Metallurgy | 8 | Active |
| US10731215B2 | Method for determining the presence or absence of methylation in a sample | Emerging Cross-Sectional Technologies | 4 | Active |
| US7972784B2 | Method for quantification of methylated DNA | Emerging Cross-Sectional Technologies | 3 | Active |
| US8101359B2 | Method for determining risk of relapse of breast cancer following tamoxifen adjuvant therapy | Chemistry; Metallurgy | 3 | Expired |
| US8623599B2 | Method for methylation analysis | Emerging Cross-Sectional Technologies | 2 | Active |
| US9605306B2 | Methods and nucleic acids for the analysis of gene expression associated with the development of prostate cell proliferative disorders | Chemistry; Metallurgy | 2 | Active |
| US9017944B2 | Methods for the prognosis of breast cancer | Chemistry; Metallurgy | 2 | Active |
| US7381808B2 | Method and nucleic acids for the differentiation of prostate tumors | Chemistry; Metallurgy | 1 | Expired |
| US9695478B2 | Methods and nucleic acids for the analyses of cellular proliferative disorders | Chemistry; Metallurgy | 1 | Active |
| US10385402B2 | Methods and nucleic acids for analyses of cellular proliferative disorders | Chemistry; Metallurgy | 0 | Active |
| US9850532B2 | Methods and nucleic acids for the analysis of gene expression associated with the development of prostate cell proliferative disorders | Chemistry; Metallurgy | 0 | Active |
| US11186879B2 | Methods and nucleic acids for analyses of cellular proliferative disorders | Chemistry; Metallurgy | 0 | Active |
| US7951563B2 | Methods and nucleic acids for analysis of cellular proliferative disorders | Chemistry; Metallurgy | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.